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Abstract
Mutational processes underlie cancer initiation and progression. Signatures of these processes in 
cancer genomes may explain cancer etiology and could hold diagnostic and prognostic value. We 
developed a strategy that can be used to explore the origin of cancer-associated mutational 
signatures. We used CRISPR-Cas9 technology to delete key DNA repair genes in human colon 
organoids, followed by delayed subcloning and whole-genome sequencing. We found that 
mutation accumulation in organoids deficient in the mismatch repair gene MLH1 is driven by 
replication errors and accurately models the mutation profiles observed in mismatch repair–
deficient colorectal cancers. Application of this strategy to the cancer predisposition gene NTHL1, 
which encodes a base excision repair protein, revealed a mutational footprint (signature 30) 
previously observed in a breast cancer cohort. We show that signature 30 can arise from germline 
NTHL1 mutations.
Cancer arises through the sequential accumulation of mutations in somatic cells. The overall 
mutational burden of somatic cells is determined by a balance between DNA damage and 
repair activity. Mutational processes leave specific signatures, as defined by systematic 
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analysis of mutation characteristics across many independent cancer sequencing data sets 
(1). A recent study showed that a set of mutational signatures in genome-wide mutation 
collections of breast cancers predicts deficiency of BRCA1 and BRCA2, as well as 
sensitivity to PARP [poly(adenosine diphosphate–ribose) polymerase] inhibition (2). To 
date, the main approach to link specific mutational signatures to underlying molecular 
mechanisms has involved associating cancer mutations with defined exposures to 
carcinogens, such as tobacco smoke (3) and ionizing radiation (4), or with the absence of 
specific DNA repair proteins, such as components of the DNA mismatch repair (MMR) (1) 
and nucleotide excision repair (NER) pathways (5). However, multiple processes are 
simultaneously active in tumors with highly unstable genomes, which makes it difficult to 
causally link the presence of specific mutational signatures to DNA repair deficiency.
Organoid technology allows for the long-term in vitro expansion of epithelial tissues, 
starting from a single adult stem cell. Such organoids remain genetically stable over long 
periods of time (6). We have previously shown that clonal organoid cultures can be used for 
in-depth pattern analysis of mutations that accumulate throughout life in tissue-specific adult 
stem cells (7, 8). Moreover, organoids can be readily modified using CRISPR-Cas9 genome 
editing (9). Mammalian species differ greatly in their DNA repair capacity and will thus 
respond differently to mutagenic stress (10, 11), and mutation types and numbers will vary 
over a lifetime (7). We used CRISPR-Cas9 genome editing in human intestinal organoid 
cultures to systematically decipher the mutational consequences of DNA repair deficiency.
To establish a tool for dissecting mutational signatures in human organoid cultures, we 
introduced loss-of-function mutations in the MMR gene MutL homolog 1 (MLH1). 
Inactivating mutations in MMR genes, including MLH1, predispose people to colorectal 
cancer (12, 13). These tumors are characterized by an immense mutational load, such as 
base substitutions and small insertions and deletions (INDELs) at short repeat sequences in 
the genome, referred to as micro-satellite instability (MSI) (13). We used organoids derived 
from human normal colon epithelium, because this allowed us to study the effect of 
disruption of single DNA repair genes in an otherwise normal genetic background. 
Moreover, human colonic organoids are as close as possible to the cell-of-origin of 
colorectal cancer (14). To inactivate MLH1 in normal human colonic organoids, we used 
CRISPR-Cas9 technology to insert a puromycin-resistance cassette into the second exon of 
the MLH1 gene (Fig. 1A and fig. S1A). After puromycin selection, we clonally expanded 
single organoids and subsequently genotyped these to confirm correct biallelic targeting 
(figs. S1, A and B, and S2A). Gene inactivation was verified by quantitative reverse 
transcription polymerase chain reaction (qRT-PCR), revealing a substantial reduction in 
MLH1 mRNA expression in MLH1 knockout (MLH1KO) organoids, most likely due to the 
degradation (through nonsense-mediated decay) of nonsense mRNAs transcribed from the 
mutant alleles (Fig. 1C). Western blot analysis confirmed the loss of MLH1 protein 
expression in the MLH1KO organoids (Fig. 1E).
Next, we passaged the MLH1KO and parental normal human colon organoids for 2 months 
to allow cells to accumulate sufficient mutations required for downstream analyses (fig. 
S1C). We then used flow cytometry to establish subclonal cultures of single cells (fig. S1C) 
and expanded these until sufficient DNA could be obtained (7). Both clonal and subclonal 
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cultures were subjected to whole-genome sequencing (WGS) analyses to identify the 
mutations that accumulated between the two clonal expansion steps and to correlate their 
appearance with time (Fig. 2A). As expected, MLH1KO organoids showed an increased base 
substitution load (27.7 ± 4.9 mutations per genome per day) compared with normal 
organoids (3.8 ± 1.2 mutations per genome per day), as well as a change in type of base 
substitutions (increase in C>T transitions). Similarly, the MLH1KO organoids displayed an 
increased number of INDELs (Fig. 2A), which were predominantly single–base-pair 
deletions (Fig. 2B) at mononucleotide repeats (Fig. 2C). This confirmed that deletion of 
MLH1 is sufficient to generate the mutator phenotype observed in MMR-deficient tumors. 
As expected, we did not observe an increase in structural variations.
Somatic mutations are unevenly distributed throughout the genomes of most cancers (15, 16) 
and normal adult stem cells (7). In general, base substitutions are more frequent in 
heterochromatic and late-replicating regions of the genome. It has been reported that specific 
DNA repair activity, including MMR (17) and NER (18), underlies this variation in regional 
mutation rates, as tumors lacking essential components of either of these DNA repair 
pathways show a less biased genomic distribution. To directly test this, we performed a 
genome-wide analysis of replication timing (Repli-seq) (19) on human intestinal organoids. 
We defined early, intermediate, and late replicating genomic regions and determined the 
relationship between somatic mutational load and replication timing. As observed in most 
cancers (16), in vitro–accumulated mutations in normal organoids were more frequent in 
late-replicating DNA (Fig. 3A). This bias was no longer present in MLH1KO cells, in line 
with the notion that MMR might be more active in euchromatic early-replicating regions of 
the genome, thereby creating variation in regional mutation rates (17). However, when we 
compared the absolute mutational loads in the genomic regions with different replication 
timing, we found that all regions (not only euchromatic early-replicating regions) showed 
increased mutation numbers (Fig. 3A). Thus, additional mutagenic processes might be active 
in the MLH1KO cells that increase mutational load throughout the genome, thereby 
removing the bias in genomic distribution.
By removing part of the newly synthesized strand, MMR is able to repairs errors—such as 
base-base mismatches and insertion and/or deletion loops at simple repeats—that are 
introduced by DNA replication polymerases (20). MLH1KO cells are characterized by 
increased levels of both base substitutions and INDELs at simple repeats (Fig. 2). An 
imbalance in mutation incorporation can arise between the leading and lagging strands 
during DNA replication, because different DNA polymerases are used with distinct fidelities 
and proofreading capacities. Additionally, the lagging strand is exposed longer as single-
stranded DNA, which is chemically less stable than double-stranded DNA and may thus be 
more vulnerable to accumulate damage (21). To define leading and lagging strands to test for 
replication strand asymmetry, we determined the location of replication origins using the 
Repli-seq data. We observed a significant replication strand asymmetry in MLH1KO cells for 
C>A, C>G, C>T, and T>C substitutions (P < 0.05, two-sided Poisson test) that was not 
observed in normal cells (Fig. 3B). MSI colorectal tumors, typically resulting from damage 
to the MMR system, show similar replicative asymmetry (21). Without functional MMR, the 
DNA polymerase errors cannot be resolved. Therefore, the additional mutagenic process that 
is active throughout the entire genome of MLH1KO cells may represent stochastic mistakes 
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by DNA replication polymerases, which were previously suggested to be important in 
mutation accumulation in human cancers (22).
We next extracted mutational signatures (fig. S3) and compared them to those described in 
the Catalogue of Somatic Mutations in Cancer (COSMIC) database, using cosine similarity 
as a measure of closeness (1, 23). As we previously reported (7), normal organoids typically 
show a contribution of a mutational signature that resembles COSMIC signature 18 (cosine 
similarity = 0.870), which is characterized by C>A transversions. Recently, a similar 
signature was described to be associated with 8-oxoguanine mutagenesis (24). In contrast, 
MLH1KO organoids were characterized by the predominant occurrence of a signature that 
resembles COSMIC signature 20 (cosine similarity = 0.792), suggesting that this signature 
reflects mistakes made by polymerases during normal DNA replication. As human intestinal 
stem cells divide approximately once every day (fig. S4), we estimate that ~25 replication 
errors occur per cell division, which are largely resolved by MMR in normal cells (Fig. 4A). 
Next, we determined the cosine similarity between the mutational profile of each sample and 
each COSMIC signature, which reflects how well the mutational profile of a sample can be 
explained by each signature individually. We included genome-wide mutation data obtained 
by analysis of individual cancer cells (expanded as clonal organoids before sequencing) 
from colon cancers derived from three different patients (materials and methods). One of 
these cancers is driven by MLH1 promoter hypermethylation and therefore lacks MMR 
activity, whereas the other two cancers are MMR proficient. Mutation accumulation in our 
MLH1KO organoids closely resembled that of MMR-deficient cancer cells and was 
markedly different from MMR-proficient cancer cells (Fig. 4B).
As our organoid-targeting strategy allowed us to define a very clean mutational signature for 
MMR deficiency, we next set out to determine signatures caused by deficiency in base 
excision repair (BER), the role of which in generating cancer-causing mutations is less well 
established than that of MMR deficiency. To this end, we inactivated the BER gene NTHL1, 
which encodes a DNA glycosylase that is involved in the removal of oxidized pyrimidines 
through initiation of the BER pathway (25, 26) (Fig. 1B and figs. S1A and S2B). Germline 
homozygous mutations in NTHL1 were recently shown to cause adenomatous polyposis and 
colorectal cancer (27). Upon gene targeting, we confirmed the loss of NTHL1 expression by 
qRT-PCR analysis (Fig. 1D) and Western blotting (Fig. 1F). Because we expected a lower 
mutation frequency with BER deficiency as compared with MMR deficiency (27), we 
cultured the NTHL1KO clones for 3 months and subsequently generated subclonal cultures 
and used WGS to analyze the mutations that specifically accumulated between the two 
clonal expansion steps (fig. S1C). As expected, the base substitution accumulation rate in 
NTHL1KO cells was approximately one-fourth of that in MLH1KO cells but approximately 
two times higher than in normal cells (Fig. 2A). Loss of NTHL1 did not result in increased 
numbers of INDELs (Fig. 2A) or structural variation.
In contrast to MLH1KO cells, NTHL1KO cells retained a nonrandom distribution of 
mutations throughout the genome, as observed for normal cells (Fig. 3A). Signature 30, 
characterized by C>T transitions, was the main contributor to the mutation spectrum 
observed in NTHL1KO cells (Fig. 4A and fig. S3C). Of note, somatic mutation analysis in 
the NTHL1KO clones did not reveal any nonsynonymous or stop-gain mutations in other 
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DNA repair genes (table S1), supporting the notion that the observed change in mutation 
accumulation can be solely attributed to NTHL1 deficiency. In agreement with the 
observations on the NTHL1KO clones (Fig. 2A), it was reported previously that colorectal 
cancers from individuals with biallelic NTHL1 germline mutations predominantly show 
C>T transitions in their exomes (27, 28). Signature 30 has previously been identified in one 
patient with breast cancer (PD13297a) analyzed by WGS (29). We examined tumor and 
germline sequences of this patient and identified a germline nonsense mutation in NTHL1 
(Fig. 4C), compounded by loss of heterozygosity in the tumor. This observation further 
corroborates the link between NTHL1 deficiency and signature 30. Mutation accumulation 
in our NTHL1KO organoids closely resembled that in PD13297a (Fig. 4B).
We have shown that mutational signatures can be dissected by characterizing the genomic 
landscapes of genetically modified human organoid subclones. Engineered MLH1KO 
organoids validated our approach, as they accurately model the predominant mutation 
profiles observed in MMR-deficient colorectal cancers. We subsequently used our approach 
to demonstrate that a high contribution of signature 30 mutations within a tumor can be 
indicative of cancer-predisposing germline mutations in the base excision repair gene 
NTHL1. A similar strategy could be exploited to investigate the consequences of other BER 
gene deficiencies. Although signature 30 has been previously identified in one patient of a 
large breast cancer cohort, it may be indicative of predisposition to a broader range of cancer 
types. NTHL1 germline mutations appear to predispose people to multiple cancer types, 
including colorectal and breast cancer (27, 28). The strategy we have described can be used 
to study the mutational consequences of DNA repair knockouts or mutagen exposure, to 
systematically dissect mutational signatures and potentially unveil their molecular origins.
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A signature event for organoids
Human cancer genomes harbor cryptic mutational signatures that represent the 
cumulative effects of DNA damage and defects in DNA repair processes. Knowledge of 
how specific signatures originate could have a major impact on cancer diagnosis and 
prevention. One approach to address this question is to reproduce the signatures in 
experimental systems by genetic engineering and then match the signatures to those 
found in naturally occurring cancers. Drost et al. used CRISPR-Cas9 to delete certain 
DNA repair enzymes from human colon organoids. In a proof-of-concept study, they 
show that deficiency in base excision repair is responsible for a mutational signature 
previously identified in cancer genome sequencing projects.
Science, this issue p. 234
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Fig. 1. Generation of DNA repair gene knock-outs in human intestinal stem cell cultures.
Targeting strategy for the generation of MLH1 (A) and NTHL1 (B) knockout organoids 
using CRISPR-Cas9 genome editing. sgRNA, single guide RNA. (C) qRT-PCR for MLH1 in 
normal and MLH1KO organoids. Expression was normalized to GAPDH. Mean and SD 
(error bars) of n = 3 independent experiments are indicated. (D) Same as in (C), but for 
NTHL1. (E) Western blot analysis of MLH1 expression in normal and MLH1KO organoids 
(representative from n = 3). Tubulin was used as a loading control. The asterisk indicates a 
background band. (F) Same as in (E), but for NTHL1. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as a loading control.
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Fig. 2. Mutational burden in DNA repair–deficient human colonic stem cells.
(A) Number of mutations accumulated in the absence of the indicated DNA repair proteins 
per day. Base substitutions subdivided by mutation type and INDELs are shown. (B) Size 
distribution of the observed INDELs per genotype. A negative value indicates deletions and 
a positive value indicates insertions. (C) Number of INDELs located in simple repeats per 
genotype. Indicated are the number of repetitive subunits surrounding an inserted or deleted 
subunit. A value of 0 indicates that the INDEL is not located within a simple repeat.
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Fig. 3. Nonrandom genomic distribution of base substitutions in DNA repair–deficient organoids.
(A) Shown for each genotype are enrichment and depletion of base substitutions in the 
genomic regions that are replicated at the indicated stages during S phase of the cell cycle. 
Asterisks indicate a significant enrichment or depletion (P < 0.05, one-sided binomial test). 
(B) Relative levels of each base substitution type in the leading and lagging DNA strands are 
shown for each genotype. Asterisks indicate a significant difference (P < 0.05, two-sided 
Poisson test).
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Fig. 4. Signatures of mutational processes in DNA repair–deficient organoids.
(A) (Left) Mutational spectra of all base substitutions observed for each genotype. Different 
mutation types and the direct sequence context are indicated. (Right) Number of mutations 
per genome per day that can be explained by the indicated mutational signatures for each 
genotype. (B) Heat map showing the cosine similarity scores for each indicated sample and 
COSMIC signature. The samples have been clustered according to the similarity score with 
each signature. The signatures have been ordered according to their similarity, such that very 
similar signatures cluster together. Arrows indicate signatures that have been associated with 
deficiency in DNA MMR in pan-cancer analyses (1). MSI, microsatellite instability. (C) 
Mutations that have been introduced or identified in NTHL1. The blue diamond indicates 
the site where the selection marker was introduced by gene targeting in the organoids. The 
red diamond denotes the nonsense germline mutation that was identified in a patient with 
breast cancer (PD13297a). LOH, loss of heterozygosity.
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